PTC Therapeutics Lifts 2026 Guidance as Q3 Product Revenue Doubles
Warren – October 30, 2026 -- PTC Therapeutics (NASDAQ: PTCT) reported third-quarter 2026 total revenue of $358 million and raised its full-year product revenue guidance to $960 million to $990 million, up from $850 million to $950 million. Total revenue guidance for 2026 now stands at $1.29 billion to $1.32 billion.
Product revenue more than doubles on Sephience launch
Net product revenue across the commercial portfolio reached $275.9 million, against $131.0 million in the third quarter of 2025. Net product and royalty revenue combined totaled $357.6 million, compared with $201.7 million a year earlier.
Sephience (sepiapterin) generated $181.9 million, up 20% from the second quarter. US sales were $145 million and ex-US sales $37 million. More than 2,000 patients were on therapy worldwide as of September 30. CEO Matthew Klein said the launch has been a success by all measures and that PTC is on track to reach cash flow breakeven this year.